Competitive Bidding Compromise On Table As Medicare Deadline Draws Near
This article was originally published in The Gray Sheet
Medicare conferees could reach a compromise on competitive bidding in which payment for DME equipment is frozen for five years before the program is implemented
You may also be interested in...
A provision establishing clinical trial coverage for Category A devices is part of a larger consensus reached by conferees on less controversial aspects of the "Medicare Prescription Drug & Modernization Act" of 2003 (HR 1, S 1)
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.